Approximately 3 months after photodynamic therapy (PDT), the treated skin areas should be re-examined to assess the success of the treatment. Any remaining lesions can then be treated again with PDT.1
Actinic Keratosis (AK) constitutes a chronic disease. Where AKs are multiple or confluent or at sites of poor healing, patients may warrant long-term follow-up for the associated increased risk of NMSC.2
Regular screening at 6 month intervals is also recommended for patients taking immunosuppressive medications who have a high incidence of AK and skin cancer.3
Patients treated with PDT should be reassessed after 3 months and any lesions which have not completely resolved should be re-treated.1
Patients who have once developed a basal cell carcinoma (BCC) have a significantly higher risk of developing a further BCC.4 In addition, such patients are also at risk with regard to the development of further skin tumors, such as squamous cell carcinoma.4 Regular follow-up is therefore important for the early detection of local recurrences and second tumors.
The design of the follow-up depends on the risk of recurrence and the number of basal cell carcinomas treated5:
This may need to be more frequent in selected high-risk patients such as those with Gorlin-Goltz syndrome or immunosuppressed organ transplant recipients.
Patients with a high risk of developing skin cancer such as those with Gorlin-Goltz syndrome are advised to protect themselves from UV light through a combination of avoiding sunlight exposure, wearing appropriate clothing and the use of sunscreen.5
Generally speaking: In addition to regular follow-up as part of skin cancer screening, physicians should instruct their patients to perform regular self-inspection of their skin.
Conspicuous skin changes should then be clarified by a doctor as soon as possible.
UKBF-2022-006l-V01, Date of preparation: April 2022